BRIDGE

SUPPORTING

  • Ongoing phase 2 trial with up to 25 patients
  • Open-label, single-arm trial for patients with reduced renal function
  • Positioning trial to show melflufen’s treatment profile within this patient group
  • Started in Q3 2018, with the initial results expected in Q4 2019